🚨 ESMO 2026 | PANKU-Breast01 (LBA50) #esmo26 Impressive phase III results for izalontamab brengitecan (iza-bren), a bispecific EGFR/HER3 ADC, in previously treated MBC HR +ve Her2 -ve Iza-bren vs physician's choice chemotherapy: 🔹 Median PFS: 8.18 vs 4.01 months 🔹 HR 0.41 (95% CI 0.33–0.53; p<0.0001) 🔹 ORR: 40.5% vs 20.2% 🔹 Median DoR: 6.93 vs 4.21 months 🔹 ILD: 1.1% (all grade 1–2) 🔹 OS: Immature A remarkable 59% reduction in the hazard of progression or death, with manageable toxicity. Another ADC enters the increasingly crowded HR+/HER2− breast cancer landscape. @OncBrothers @myESMO @OncoAlert